BiotechTubeBiotechTube
Home/PepGen/Sarah Vacca
SV

Sarah Vacca

Executive Director, Clinical Operations

PepGen

Therapeutic Areas

Neuromuscular DiseasesNeurological Diseases

PepGen Pipeline

DrugIndicationPhase
PGN-EDODM1Myotonic Dystrophy Type 1 (DM1)Phase 2
PGN-EDO51Duchenne Muscular Dystrophy (amenable to exon 51 skipping)Phase 2
EDO Platform for CMT1ACharcot-Marie-Tooth disease type 1A (CMT1A)Preclinical
Discovery ProgramsAdditional Neuromuscular & Neurological IndicationsDiscovery

Leadership Team at PepGen

JM
James McArthur, Ph.D.
President and Chief Executive Officer
ND
Noel Donnelly, MBA
Chief Financial Officer
KK
Kasra Kasraian, Ph.D.
Chief Technical Officer
JV
Joseph Vittiglio, Esq.
Chief Business and Legal Officer
PS
Paul Streck, M.D., MBA
Executive Vice President, Head of Research & Development
EB
Emiko Bryant
Senior Vice President, HR and Administration
HP
Hayley Parker, Ph.D.
Senior Vice President, Global Regulatory Affairs & Quality
JL
Jane Larkindale, D.Phil.
Vice President, Clinical Science
PL
Pallavi Lonkar, Ph.D.
Vice President, Head of Preclinical
RL
Rod Lozano
Vice President, Information Technology
View full PepGen profile